Exelixis (EXEL) Tops Q4 EPS by 10c, offers guidance

Exelixis (NASDAQ: EXEL) reported Q4 EPS of $0.33, $0.10 better than the analyst estimate of $0.23. Revenue for the quarter came in at $480 million versus the consensus estimate of $481.81 million.

GUIDANCE:

Exelixis sees FY2024 revenue of $1.825-1.925 billion, versus the consensus of $1.829 billion.

For earnings history and earnings-related data on Exelixis (EXEL) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c